{"entity":{"id":"nct07779694","kind":"trial","name":"16-Hour Fasting Plus Serplulimab and CAPEOX as Neoadjuvant Therapy in pMMR/MSS Advanced Mid-to-Low Rectal Cancer","aka":[],"tldr":"A phase 2 trial of serplulimab in colorectal cancer, run by Zhejiang University, not yet recruiting.","summary":"16-Hour Fasting Plus Serplulimab and CAPEOX as Neoadjuvant Therapy in pMMR/MSS Advanced Mid-to-Low Rectal Cancer is a phase 2, interventional study registered as NCT07779694 by Zhejiang University, with a registry enrolment figure of 51 participants, started 2026-10-01 and due to reach its primary completion in 2028-12-31. Interventions recorded: 16-Hour Fasting; Serplulimab + chemotherapy. Conditions listed: pMMR/MSS; Locally Advanced Rectal Carcinoma; Fasting, Intermittent. Primary outcome: Pathological complete response rates. Colorectal eligibility wording from the registry: \"Histological or cytological documentation of adenocarcinoma of the rectum\". No results are recorded here; the registry entry is the source.","status":"planned","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT07779694","url":"https://clinicaltrials.gov/study/NCT07779694"}],"tags":["ctgov-ingest","colorectal-deep-dive"],"related":[],"cancers":["rectal-cancer"],"sections":[],"technologies":["checkpoint-inhibitor"],"targets":[],"drugs":["serplulimab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07779694","phase":"2","setting":"Neoadjuvant 16-Hour Fasting Combined With Serplulimab and CAPEOX for pMMR/MSS Locally Advanced Mid-to-Low Rectal Cancer: A Prospective, Single-Arm, Phase II Trial.","sponsor":"Zhejiang University","enrolled":51,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07779694/","neighbours":{"cancer":[{"id":"rectal-cancer","kind":"cancer","name":"Rectal cancer","route":"/cancers/rectal-cancer/"}],"technology":[{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"}],"drug":[{"id":"serplulimab","kind":"drug","name":"Serplulimab","route":"/drugs/serplulimab/"}],"term":[{"id":"colorectal-trials-open-today","kind":"term","name":"Colorectal cancer trials open today (registry snapshot)","route":"/terms/colorectal-trials-open-today/"}]}}